NCT02171156Approved For Marketing不适用
Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 7
研究概览
简要总结
To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (7)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT02230982Boehringer Ingelheim
Approved For Marketing
不适用
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GISTGIST - Gastrointestinal Stromal TumorNCT04148092Deciphera Pharmaceuticals, LLC
已完成
3 期
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.Gastrointestinal Stromal TumorsNCT01289028Novartis Pharmaceuticals125
Approved For Marketing
不适用
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT01931306Boehringer Ingelheim
Approved For Marketing
不适用
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast CancerNeoplasms, BreastNCT00338247Novartis